NEWS


News & events

Our seminars

This is the calendar invitation to announce our speaker (details below) and share the “save-the-date”.


​** 24/03/2026 - h. 14:00
speaker: Andrew Aplin, Associate Director, Basic Science at the Sidney Kimmel Comprehensive Cancer Center, Philadelphia (US)
title: Fueling the fire in melanoma
host: IEO-Lanfrancone
location: IFOM Conference Room **

https://www.jefferson.edu/academics/colleges-schools-institutes/skmc/departments/pharmacology/faculty-staff/faculty/aplin.html


The Aplin Laboratory is dedicated to decoding the mechanisms by which melanoma adapts to and resists modern therapeutics. The work of his group is highly translational, frequently moving discoveries from the bench into active clinical trials. Key research themes include:

  *   Bypassing Adaptive Resistance: Utilizing in vivo tumor reporter models to study signal transduction pathways. The research into ErbB3 adaptive responses is currently being translated into clinical strategies to optimize FDA-approved MEK and BRAF inhibitors.
  *   Modulating the Tumor Microenvironment: Investigating methods to trigger inflammatory forms of cell death. The goal is to remodel the "cold" tumor microenvironment into a "hot," inflamed state that is significantly more responsive to immune checkpoint inhibitors.
  *   Uveal Melanoma & Dormancy: A specialized focus on the epigenetics and metabolism of ocular melanoma. This work specifically targets tumor dormancy, seeking to understand why these cells can remain latent for years before becoming highly aggressive.

DEO Seminar: Andrew Aplin

March 24, 2026 14:00

our last paper

Sequence-specific RNA recognition drives Restrictor-mediated termination of extragenic transcription.

Sequence-specific RNA recognition drives Restrictor-mediated termination of extragenic transcription.

Polizzese D, Mandana GM, Russo M, Polletti S, Prosperini E, Ciossani G, Monzani S, Scietti L, Rodighiero S, Gualdrini F, Piccolo V, Natoli G
Mar , 2026

highlight

The EU-LIFE Postdoctoral Exchange Programme

The EU-LIFE Postdoctoral Exchange Programme

highlight

PROSIBLAD tra i vincitori del grant S4I!

PROSIBLAD tra i vincitori del grant S4I!

Our SCIENCE


Research & technology

Our science
Principal Investigators
Technological Units
Translational Research Programs
Technology Transfer Office (IEO-TT)

Our MENTORING


Education & training

Our mentoring
Undergraduate Students
PhD Students
Postdoctoral Fellows
Technicians

Our ALLIANCES


Partners & Networks

JOIN us


Explore our open positions

Over the past 30 years since DEO’s founding, numerous scientists have launched and advanced their careers here. This has created a broad community of researchers who, despite being spread across institutes worldwide, still cherish their experiences at IEO and maintain strong ties to the department. In 2018, DEO held its inaugural Alumni meeting, bringing together 50 former PhD students, postdocs, and Group Leaders, now Principal Investigators or Institute Directors internationally, to reconnect and engage in scientific discussions.

READ
Ernesto Guccione

Ernesto Guccione

IEO Postdoc 2004‑2008

VIEW DETAILS

SUPPORT us


In Italy, taxpayers have the option to donate 0.5% of their taxes to non-profit organizations through the “Cinque per mille” (5x1000) scheme.

When submitting your income tax return via the 730 or CUD forms, you can designate 5x1000 of your tax to the European Institute of Oncology (IEO), helping to advance research, innovation, and treatment.

Clinical activities at IEO are conducted at the IEO Hospital on Via Ripamonti.
IEO’s core values focus on prioritizing patients’ needs and pursuing ongoing self-improvement to achieve excellence in clinical care and research, all within a multidisciplinary framework